文献速递脑血管病

急性缺血性卒中远端血管闭塞:重新审视患者选择与再灌注策略

Distal Vessel Occlusions in Acute Ischemic Stroke: Reframing Patient Selection and Reperfusion Strategies.
PubMed 文献 · Neurology · 2026-08-11

本文针对急性缺血性卒中远端和中血管闭塞(DMVO)的机械取栓治疗进行叙述性综述。近期随机试验和荟萃分析在宽泛定义的DMVO人群中未显示血管内治疗优于最佳药物治疗,且颅内出血率数值上更高。作者认为中性结果反映了DMVO定义和表型的异质性、严重程度和结局量表的局限性、解剖和设备相关的安全限制以及小血管血栓取出的独特机制,而非缺乏生物学疗效,支持将DMVO视为需要量身定制选择、技术和结局评估的独特综合征。

要点

  • DMVO占缺血性卒中相当比例,即使症状轻至中度也可导致长期残疾或死亡。
  • 近期随机试验在宽泛DMVO人群中未显示EVT优于BMT,颅内出血率数值上更高。
  • 治疗效应可能取决于精细的患者选择和优化的远端特异性技术。

核心结论

  • DMVO卒中应被视为需要量身定制选择、技术和结局评估的独特综合征,而非近端EVT的失败延伸。

研究设计与样本

  • 叙述性综述,对现有证据进行解释性综合,未报告系统检索范围。

主要发现

  • 近期随机试验和荟萃分析在宽泛定义的DMVO人群中未显示EVT优于BMT的功能获益。
  • MT组观察到颅内出血率数值上更高。
  • 注册研究发现许多DMVO患者尽管接受BMT仍遗留残疾。
  • 新兴试验数据提示治疗效应可能取决于精细的患者选择和优化的远端特异性技术。

关键数值与推荐

  • DMVO定义和表型的异质性、严重程度和结局量表的局限性、解剖和设备相关的安全限制以及小血管血栓取出的独特机制可能解释中性结果。

临床怎么用

  • 识别可能从远端再灌注中获益的亚组需综合考虑临床、影像、解剖和血栓相关特征。
  • 新兴技术和药物策略包括DMVO特异性设备适配、动脉内溶栓和混合再灌注方法,旨在减少机械创伤同时保留及时再通的优势。

局限性

  • 本文为叙述性综述,未报告系统检索策略,证据解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke because of large vessel occlusion (LVO), but distal and medium vessel occlusions (DMVOs) remain a gray zone. DMVOs account for a substantial proportion of ischemic strokes and can cause long-term disability or death despite often presenting with only mild to moderate symptoms. Their biologic and anatomic diversity-including small vessel caliber, variable perfusion territories, collateral dependence, and complex access pathways-creates distinct patterns of natural history, treatment responsiveness, and procedural risk compared with proximal LVO. Recent randomized trials and meta-analyses, conducted in broadly defined DMVO populations, did not demonstrate functional benefit of endovascular therapy (EVT) over best medical therapy (BMT) and observed numerically higher rates of intracranial hemorrhage with MT. These neutral results have fueled skepticism and guideline recommendations against routine EVT for DMVO stroke; however, they coexist with emerging trial data suggesting that treatment effects may depend on refined patient selection and optimized, distal-specific techniques, as well as with registry findings indicating that many patients with DMVO remain disabled despite BMT. In this narrative, we provide an interpretative synthesis of the available evidence to argue that the apparent discrepancy between biologic plausibility and neutral trial results reflects, at least in part, heterogeneity of DMVO definitions and phenotypes, limitations of severity and outcome scales, anatomy- and device-related safety constraints, and the unique mechanics and biology of small vessel thrombus retrieval rather than an absence of biologic efficacy. We highlight clinical, imaging, anatomic, and thrombus-related features which may help identify subgroups more likely to benefit from distal reperfusion and discuss emerging technical and pharmacologic strategies-including DMVO-specific device adaptations, intraarterial thrombolysis, and hybrid reperfusion approaches-which aim to reduce mechanical trauma while preserving the advantages of timely recanalization. Together, these considerations support a shift from viewing distal MT as a failed extension of proximal EVT to recognizing DMVO stroke as a distinct syndrome that requires tailored selection, techniques, and outcome assessment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jabłońska M, Ribó M. Distal Vessel Occlusions in Acute Ischemic Stroke: Reframing Patient Selection and Reperfusion Strategies. Neurology. 2026. PMID: 42579828. doi:10.1212/WNL.0000000000218440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。